Acute Myeloid Leukemia

Midostaurin Improves Survival in Subset of Acute Myeloid Leukemia (12-15-2015)

The targeted agent, midostaurin, has demonstrated a survival improvement among patients with acute myeloid leukemia (AML) that has the TMS-like tyrosine kinase 3 (FLT3) mutation. These results were presented at a plenary session at the 2015 annual meeting... Continue Reading

Promising Survival for AML Patients Treated with Stem Cells from Related Half Matched Donor (07-30-2015)

Patients with acute myeloid leukemia (AML) may have a promising new treatment option. Research shows that stem cell transplant from a “half matched” related donor plus chemotherapy results in similar survival as a transplant from an unrelated matched... Continue Reading

CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients (01-28-2015)

The U. S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigational drug CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. Acute... Continue Reading

Orphan-drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients (12-8-2014)

(OMNI-CancerConnect) Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the US Food and Drug Administration (FDA) has granted... Continue Reading

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (08-8-2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod... Continue Reading

Mylotarg Reduces Risk of Relapse in Childhood AML (12-20-2013)

Mylotarg® (gemtuzumab ozogamicin)—a drug that was withdrawn from the market in 2010 because of uncertain benefit and safety concerns—reduces the risk of relapse in children and young adults with acute myeloid leukemia (AML). These results were presented... Continue Reading

Busulfex Superior to Total Body Irradiation in AML in First Remission (11-1-2013)

Myeloablative conditioning with cyclophosphamide and Busulfex® (intravenous busulfan) was associated with better leukemia-free and overall survival than conditioning with cyclosphosphamide and total-body irradiation (TBI) in patients with acute myeloid... Continue Reading

CPX-351 Highly Active in Older Patients with AML (01-18-2013)

CPX-351 is highly active in all patient subgroups and produced the greatest benefits in response rate and reduction in 60-day mortality compared to standard therapy in older patients with secondary acute myeloid leukemia and adverse cytogenetics, according... Continue Reading

Combination of Revlimid and Vidaza Beneficial in Untreated Elderly Patients with AML (01-14-2013)

The sequential combination of Vidaza® (azacitidine) and Revlimid® (lenalidomide) shows evidence of clinical activity as initial therapy for older patients with acute myeloid leukemia, according to the results of a phase II study presented at the 54th... Continue Reading

Quizartinib Shows Promise in Treatment-Resistant AML (12-19-2012)

The targeted agent quizartinib showed promise in the treatment of a subset of patients with treatment-resistant acute myeloid leukemia (AML), according to the results of a study presented at the 54th Annual Meeting of the American Society of Hematology... Continue Reading

« Previous PageNext Page »